Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
NVS [NYSE]
Novartis AG
Index- P/E23.66 EPS (ttm)4.33 Insider Own- Shs Outstand2.71B Perf Week-1.08%
Market Cap277.75B Forward P/E18.45 EPS next Y5.55 Insider Trans- Shs Float460.99M Perf Month2.05%
Income10.66B PEG2.89 EPS next Q1.07 Inst Own9.90% Short Float0.54% Perf Quarter4.75%
Sales53.63B P/S5.18 EPS this Y16.20% Inst Trans0.04% Short Ratio1.40 Perf Half Y22.20%
Book/sh29.39 P/B3.49 EPS next Y6.56% ROA10.50% Target Price104.57 Perf Year24.82%
Cash/sh4.98 P/C20.57 EPS next 5Y8.20% ROE18.60% 52W Range81.41 - 103.80 Perf YTD13.70%
Dividend2.82 P/FCF75.41 EPS past 5Y3.20% ROI10.50% 52W High-1.29% Beta0.53
Dividend %2.75% Quick Ratio1.20 Sales past 5Y3.50% Gross Margin67.70% 52W Low25.86% ATR1.32
Employees133413 Current Ratio1.40 Sales Q/Q-2.00% Oper. Margin22.70% RSI (14)56.57 Volatility0.86% 1.01%
OptionableYes Debt/Eq0.29 EPS Q/Q23.50% Profit Margin24.50% Rel Volume0.67 Prev Close103.31
ShortableYes LT Debt/Eq0.19 EarningsApr 23 BMO Payout50.90% Avg Volume1.77M Price102.46
Recom1.80 SMA201.10% SMA502.80% SMA20011.19% Volume1,184,329 Change-0.82%
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Apr-02-07Reiterated Banc of America Sec Buy $66 → $65
Apr-17-15 05:10PM  Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog
01:17PM  FDA approves generic version of top-selling MS drug Copaxone
10:09AM  Maverick Capital Increases Stake in Novartis
09:21AM  Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the Tape
08:51AM  [video]Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom at TheStreet
04:08AM  Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and Commercialization of Immuno-Oncology Products Derived from its Proprietary STING-Targeted CDN Platform Technology at noodls
Apr-16-15 05:00PM  Pfizer's Ibrance Study Stopped Early on Favorable Data - Analyst Blog
02:57PM  Bristol-Myers Deal Flags Three Gene-Therapy Picks at Barrons.com
02:39PM  Momenta, Novartis Win FDA Nod For Generic Copaxone at Investor's Business Daily
02:26PM  FDA approves first generic version of Teva MS drug Copaxone Reuters
12:48PM  Exclusive: GlaxoSmithKline shutting Moon office; 274 employees affected at bizjournals.com
12:38PM  Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg » at noodls
10:50AM  Receptos MS Drug Succeeds Against Ulcerative Colitis at Investor's Business Daily
Apr-15-15 06:10PM  FDA approves new type of heart failure drug from Amgen
01:57PM  Biotech IPOs Ignite As Aduro Doubles On First Day at Investor's Business Daily
11:49AM  Pfizer, Biogen, AbbVie Get Good Drug-Trial News at Investor's Business Daily
10:52AM  3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
01:24AM  Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients » at noodls
01:15AM  Aduro Biotech hits 'unicorn' exit with upsized $119M IPO at bizjournals.com
Apr-14-15 06:23PM  Aduro IPO pricing values drugmaker at $1 bln Reuters
06:10PM  Eurozone Government Bonds Are Cozying Up To Negative Yield
04:00PM  Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test at Forbes
02:37PM  AstraZeneca's Onglyza Ups Risk Of Death, FDA Says at Investor's Business Daily
01:30PM  Five companies that may be looking to buy Ariad Pharmaceuticals at bizjournals.com
Apr-13-15 05:25PM  What you need to know before buying into Europe at MarketWatch
01:24AM  Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians » at noodls
Apr-10-15 06:01PM  Business decency for dummies: 10 lessons from the Pao trial at bizjournals.com
11:35AM  AstraZeneca's Onglyza Ups Risk Of Death, FDA Says at Investor's Business Daily
10:27AM  Putin vs. The Accountant at Bloomberg
10:26AM  Container Store's Virtue vs. Profit at Bloomberg
10:25AM  The Forever Pill: Novartis's Quest for an Anti-Aging Drug at Bloomberg
Apr-09-15 09:30AM  The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases
Apr-08-15 05:36AM  Why Kina Grannis Chose YouTube Over Record Label at MarketWatch
Apr-07-15 09:06AM  Patent dispute settlement to benefit Penn cancer therapy partnership at bizjournals.com
08:02AM  Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched at TheStreet
07:33AM  Big pharma turns to small biotechs for edge in cancer treatment at Financial Times
Apr-06-15 03:00PM  Aduro Biotech hikes IPO target to $93 million at bizjournals.com
09:24AM  Juno Therapeutics Settles Patent Dispute With Novartis at The Wall Street Journal
Apr-03-15 07:25AM  GlaxoSmithKline to move 150 Cambridge vaccine research jobs out of state at bizjournals.com
Apr-02-15 02:35PM  Proteon founder Franano links InvestMidwest's past and future at bizjournals.com
02:14PM  The Eyes Have It? Novartis is Accused of Interfering With Trials for Avastin at The Wall Street Journal
01:45PM  GlaxoSmithKline to open global R&D center in Rockville at bizjournals.com
Apr-01-15 05:17PM  Wave Of Biosimilars Set To Roil Pharma
02:05PM  Why Is Pfizers Revenue Stream Declining?
12:31PM  What are examples of major companies in the drugs sector? at Investopedia
12:07PM  How is a Spinoff Worth $100 Billion? See AbbVie at Investopedia
10:06AM  Pfizers Global Established Pharmaceutical Segment
08:02AM  U.S. Drugmakers Facing First Wave Of Biosimilars at Investor's Business Daily
Mar-31-15 06:00PM  Making Money With Charles Payne: 03/31/15 at Fox Business
04:50PM  The Future of Big Pharma Stocks at Investopedia
04:27PM  Array BioPharma CEO Sees Big Opportunities in the Future at TheStreet
04:06PM  Pfizers Global Vaccines, Oncology & Consumer Healthcare Segment
04:04PM  Novartis Gets FDA Approval for Oral Formulation of Exjade - Analyst Blog
03:49PM  Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog
12:52PM  Cooper Companies (COO) Stock Slightly Lower Today Despite Increased Price Target at TheStreet
12:06PM  Pfizers Global Innovative Pharmaceutical Segment
09:54AM  What I Hope Everyone Learns From PBS' Big Cancer Documentary at Forbes
09:39AM  Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks at TheStreet
Mar-30-15 05:53PM  Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload » at noodls
05:06PM  Amgen loses another round in its battle to fend off a biosimilar rival at MarketWatch
02:06PM  Biopharmaceutical Business: Why Its Important for Pfizer
10:03AM  Here's What '60 Minutes' Didn't Tell You About The 'Miracle' Glioblastoma Treatment at Forbes
06:42AM  Payout time in Europe as dividends soar at CNBC
06:34AM  European Stocks Rise as Confidence in Economic Recovery Grows at TheStreet
01:23AM  Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group » at noodls
Mar-29-15 10:40PM  Claire Underwood, $70M and the verdict heard around Silicon Valley are on the minds of our women to watch this week at bizjournals.com
11:00AM  Medics welcome GSK deal to provide meningitis B vaccine at Financial Times
Mar-28-15 01:05AM  Farallon Capital Increases Position in Allergan
Mar-25-15 05:20PM  Ligand Pharmaceuticals: Biotech's Jack Of All Trades at Investor's Business Daily
01:14PM  Science, patients driving rare disease drug research surge
10:59AM  From Snitch Pill to Xbox Sensors, Novartis Goes Digital
Mar-24-15 02:53PM  Johnson & Johnson May See EPS Drag Through 2018 at Barrons.com
Mar-23-15 04:14PM  Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog
02:58PM  11 Promising New Drugs Expected to Make Billions in Sales at TheStreet
11:05AM  Eminence Capital Downs Position in Valeant Pharmaceuticals
10:06AM  Rationale for the PharmacyclicsAbbVie Merger
Mar-22-15 08:15AM  Week in Review: Big deals, lawsuits and bankruptcies dominate the news at bizjournals.com
Mar-21-15 07:10AM  Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients » at noodls
Mar-20-15 05:00PM  Judge rejects Amgen bid to stop biosimilar drug at bizjournals.com
02:00PM  New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients » at noodls
12:20PM  Amgen Loses Bid to Block a Biosimilar Version of its Best-Selling Drug at The Wall Street Journal
Mar-19-15 09:45PM  Fast-growing Triad technology firm makes acquisition, receives $20M infusion of capital at bizjournals.com
06:16PM  Judge Denies Amgen's Request to Block Novartis's Biosimilar of Neupogen at The Wall Street Journal
04:53PM  Novartis Wins Judges Approval to Sell First-of-Kind Copycat at Bloomberg
09:03AM  5 Breakout Stocks to Trade for Gains After the Fed's Bombshell at TheStreet
Mar-18-15 02:20PM  Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog
01:00PM  To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher at bizjournals.com
10:51AM  Novartis Division is Charged with Sex Discrimination by Former Employees at The Wall Street Journal
08:55AM  Pharmalot.. Pharmalittle: We're Catching Up On Novartis, Actavis and Lots More!! at The Wall Street Journal
06:30AM  Alcon targeted in $110M gender discrimination lawsuit at bizjournals.com
Mar-17-15 02:23AM  Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer » at noodls
Mar-16-15 03:06PM  What Were Johnson & Johnsons Outstanding Expenses?
02:26PM  Novartis Pays $12.6M Fine for Giving Inaccurate Pricing Data to Medicare at The Wall Street Journal
12:06PM  France, Ireland, and Spain Report Negative Inflation
11:05AM  Johnson & Johnsons Revenue Stream Increased in 2014
Mar-13-15 12:22PM  Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin » at noodls
11:19AM  Par Pharmaceutical Files To Return To Stock Market at Investor's Business Daily
Mar-12-15 07:05PM  Exploring Johnson & Johnsons Pharmaceuticals Segment
03:06PM  Johnson & Johnsons Global Business Strategy Promotes Growth
11:11AM  XOMA Reports Narrower Y/Y Loss in Q4, Misses on Revs - Analyst Blog
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company's Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerSep 22Buy15.00325,0004,875,0004,644,328Sep 24 05:42 PM